

TRANSMITTAL LETTER TO THE UNITED STATES

DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A FILING UNDER 35 U.S.C. 371

ZIELINSKI

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/890479

INTERNATIONAL APPLICATION NO.

PCT/US00/01923

INTERNATIONAL FILING DATE

26 January 2000

PRIORITY DATE CLAIMED

27 January 1999

TITLE OF INVENTION

HESPERETIN PRO-FORMS WITH ENHANCED BIOAVAILABILITY

APPLICANT(S) FOR DO/EO/US

ZIELINSKI LABORATORY

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). **Unexecuted**
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Certificate of Mailing by Express Mail **EL617043315US**
23. ☒ Other items or information:
REPLACEMENT SHEET (copy)

097 890479

PCT/US00/01923

ZIEL1100

24. The following fees are submitted:

CALCULATIONS PTO USE ONLY

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO **\$1000.00**
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **\$860.00**
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **\$710.00**
- ☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) **\$690.00**
- ☒ International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) **\$100.00**

ENTER APPROPRIATE BASIC FEE AMOUNT =**\$100.00**

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☒ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$130.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	0 - 20 =	0	x \$18.00	\$0.00	
Independent claims	8 - 3 =	5	x \$80.00	\$400.00	
Multiple Dependent Claims (check if applicable)			<input type="checkbox"/>	\$0.00	

TOTAL OF ABOVE CALCULATIONS =**\$630.00**

- ☒ Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.

\$315.00**SUBTOTAL =****\$315.00**

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$0.00**TOTAL NATIONAL FEE =****\$315.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).

☐**\$0.00****TOTAL FEES ENCLOSED =****\$315.00**

Amount to be:	\$
refunded	
charged	\$

- a. ☒ A check in the amount of **\$315.00** to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **50-1355**. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Lisa A. Haile, Ph.D.
Gray Cary Ware Freidenrich LLP
 4365 Executive Drive, Suite 1600
 San Diego, California 92121
 (858) 677-1456
 (858) 677-1465



SIGNATURE

Lisa A. Haile, Ph.D.

NAME

38,347

REGISTRATION NUMBER

July 27, 2001

DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jan E. Zielinski
Serial No.: Unassigned
Filed: July 27, 2001
Title: HESPERETIN PRO-FORMS WITH ENHANCED BIOAVAILABILITY

Commissioner for Patents
Washington, D.C. 20231

DECLARATION OF MAILING BY "EXPRESS MAIL"

I Mikhail Bayley declares as follows:

1. I reside at 4551 W. TILMADGE DR and am an employee of Gray Cary Ware & Freidenrich LLP, 4365 Executive Drive, Suite 1600, San Diego, CA 92121-2189.
2. On 07/27/01, I deposited in the mail, "Express Mail Post Office to Addressee" service of the United States Postal Service the contents of the envelope for which "Express Mail" receipt No. **EL617043315US** was addressed to: Commissioner of Patents, Washington, D.C. 20231.
3. Attached hereto is a true copy of the "Express Mail" receipt no. **EL617043315US**.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the above-identified application or any patents issued thereon.

Date: 07/27/2001

Mikhail Bayley


IN THE UNITED STATES RECEIVING OFFICE

In re Application of:
Zielinski Laboratory, et al.

Serial No.: PCT/US00/01923

Filed: 26 January 2000

For: HESPERETIN PRO-FORMS WITH
ENHANCED BIOAVAILABILITY

) CERTIFICATE OF MAILING BY "EXPRESS MAIL"
) "EXPRESS MAIL" MAILING LABEL NO. EL476993069US
) DATE OF DEPOSIT 30 May 2000. I HEREBY CERTIFY THAT
THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED
STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO
ADDRESSEE" SERVICE UNDER 37 C.F.R. 1.10 ON THE DATE
INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT
COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231
) Mikhail Bayley
(TYPED OR PRINTED NAME OF PERSON MAILING PAPER OR FEE)
) 
(SIGNATURE OF PERSON MAILING PAPER OR FEE)

Box PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO INVITATION TO CORRECT

Sir:

Responsive to the Invitation to Correct Defects in the International Application mailed on 28 February 2000, submitted herewith are the required powers of attorney. Additionally, submitted is replacement page 1 of form PCT/RO/101 indicating the correct spelling of "HESPERETIN" in the title and page 1 of the description also indicating the correct spelling of "HESPERETIN" in the title.

Please charge any fees due to Deposit Account No. 50-1355.

Respectfully submitted,

Date:

5/30/00



Lisa A. Haile, Ph.D.
Registration No. 38,347

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1600
San Diego, California 92121-2189
Telephone: (619) 677-1456
Facsimile: (619) 677-1465

09/890479

PATENT
ATTORNEY DOCKET NO: ZIEL1100WO


HESPERETIN PRO-FORMS WITH ENHANCED BIOAVAILABILITY

FIELD OF THE INVENTION


5 This invention relates generally to the field of bioflavanoids, and more specifically to forms of bioflavanoids that increase their bioavailability, and to the use of these compounds for the treatment of disease.

BACKGROUND OF THE INVENTION

10 Hesperidin and the a glycone of hesperidin, hesperetin, are flavonoids found in lemons, grapefruits, tangerines, and oranges, and have the following structures:



Hesperidin



Hesperetin

PATENT APPLICATION SERIAL NO. _____

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

08/03/2001 SNAJARRO 00000072 09890479

01 FC:963	50.00	OP
02 FC:254	65.00	OP
03 FC:965	200.00	OP

PTO-1556

(5/87)